logo
Walking and Diet Boost Cognition in At-Risk Adults

Walking and Diet Boost Cognition in At-Risk Adults

Medscape2 days ago
Growing evidence suggests that lifestyle interventions such as walking may help slow cognitive decline in individuals with the apolipoprotein E ( APOE ) ε4 allele, who have a genetically higher risk of developing Alzheimer's disease (AD) — and may even provide greater benefits than in noncarriers.
Preliminary findings from a new study show that while men and women APOE ε4 carriers experienced steeper declines in cognition over a 10-year period, regular walking appeared to mitigate these effects by preserving global cognition and executive function.
The results underscore the value of accessible physical activity programs for individuals genetically at risk for AD, study investigator Cindy Barha, PhD, Canada Research Chair in Neuroscience, Brain Health, and Exercise, and assistant professor, Faculty of Kinesiology, University of Calgary, Alberta, Canada, told Medscape Medical News .
'We can start telling people that if you're at risk, we know this one thing — walking — will be beneficial for you,' Barha said, adding this is part of an overall effort to 'start personalizing our interventions so we can maximize benefit.'
The findings were presented on July 29 at the Alzheimer's Association International Conference (AAIC) 2025.
Risk Variation by Sex
APOE ε4 accounts for almost 50% of the genetic risk for late-onset AD, but evidence suggests the risk is more pronounced in women than men. One copy of this allele is associated with a twofold increased risk in men and an eightfold greater risk in women, while two copies are associated with a fourfold increased risk in men and a 12-fold increased risk in women, Barha said.
'We know exercise and walking are good for the brain, and we wondered whether they would be even more beneficial for ε4 carriers and if they're sex-dependent.'
Meanwhile, research showed that the ε2 version of APOE may protect against cognitive decline compared with the ε3 allele, which is the most common and neutral variant.
'We also wondered if exercise would provide a kind of 'double hit' in ε2 carriers,' Barha said. 'If you're an ε2 carrier and you're walking a lot, maybe you're going to be super protected.'
The analysis included 2981 participants with a mean age of 74 years, from the Health, Aging, and Body Composition (Health ABC) study. It began in 1997 with a cohort of cognitively unimpaired community-dwelling older adults in Memphis, Tennessee, and Pittsburgh.
Walking was self-reported and assessed annually. Participants were queried about their walking habits, and walkers were asked about the total number of minutes they engaged in this activity over the past 7 days.
To assess cognition, researchers used the Digit Symbol Substitution Test (DSST), which measures a range of cognitive functions such as attention, working memory, and information processing, and the Modified Mini-Mental State Exam (3MS), a tool for evaluating global cognition. Both tests were administered at baseline and approximately every 2 years over a 10-year period. Researchers categorized APOE genotypes into ε2, ε3, and ε4 groups.
Study results showed that APOE ε4 carriers — both men and women — experienced steeper declines on both cognitive tests than ε3 carriers. Among women, the decline was significant on the DSST (β = -0.10; P < .001) and the 3MS (β = -0.13; P < .001). In men, the decline was also significant on the DSST (β = -0.07; P = .005) and more pronounced on the 3MS (β = -0.22; P < .001).
The APOE ε2 allele appeared protective against cognitive decline, but only in women on the 3MS (β = 0.15; P = .002).
Simple Activity, Strong Impact
Walking showed the strongest protective effect on both cognitive measures in APOE ε4 carriers of both sexes. A 10% increase in walking was associated with a 4.7% improvement in complex thinking performance over time in women and a 2.6% improvement in men. For global cognitive performance, the same increase in walking was linked to an 8.5% improvement in women and a 12.0% improvement in men.
Regular walking may help preserve cognition through several potential mechanisms, the authors noted. These include enhancing cerebral blood flow — improving the delivery of oxygen and nutrients to the brain — increasing levels of brain-derived neurotrophic factor, which supports neurogenesis and synaptic plasticity, promoting angiogenesis, and reducing neuroinflammation and oxidative stress.
Barha speculated that because APOE ε4 carriers begin with lower cognitive performance and decline more rapidly, they may have more room to improve and therefore stand to gain more from walking interventions. The findings highlight a key takeaway for people at elevated risk for dementia: Doctors should promote regular walking for their patients, especially as they age and if they have an elevated risk for dementia, she said.
Still to be determined are the optimal intensity and frequency of walking — and whether other forms of exercise may offer similar benefits for ε4 carriers.
Looking ahead, the research team plans to study the impact of physical activity earlier in life. 'A lot of Alzheimer's disease biomarkers start to accumulate in the brain during midlife — not when you're 70 years old or already showing signs of cognitive decline, but 20 years before that,' Barha noted.
One limitation of the study is that walking was self-reported; however, Barha noted that data collected through actigraphy closely correlates with self-reported activity levels.
Another limitation of the study was its focus solely on walking. The authors noted that if data on more vigorous activities like running and weight training had been included, the observed impact on slowing cognitive decline in this high-risk group might have been even greater. Additionally, the study did not account for other factors known to affect cognition, such as diet, stress, and sleep.
Greater Cognitive Gains for APOE ε4 Carriers
Building on these findings, results from another study presented on July 28, 2025, at the AAIC suggested that the benefits of physical activity and other lifestyle interventions may be even greater for APOE ε4 carriers than noncarriers.
The meta-analysis pooled data from three randomized clinical trials involving older adults at risk for dementia or with mild cognitive impairment (MCI) who had known APOE status: the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER; n = 1109), the Multidomain Alzheimer Preventive Trial (MAPT; n = 934), and the Japan-Multimodal Intervention Trial for Prevention of Dementia (J-MINT; n = 426).
FINGER and J-MINT randomly assigned participants to lifestyle interventions — including physical activity, healthy diet, cognitive training, and risk monitoring — or control groups.
The MAPT combined lifestyle interventions with omega-3 supplements; for this analysis, participants receiving only supplements were excluded, and those receiving lifestyle interventions with or without supplements were combined.
Researchers estimated cognitive change using each trial's original primary outcome: A composite cognition score based on multiple neurocognitive tests. The analysis compared carriers of one or two APOE ε4 alleles with noncarriers.
Preliminary results showed greater benefits of the intervention among APOE ε4 carriers than noncarriers at 24 months for both global cognition and executive function. The overall effect size for the composite score among carriers was 0.282 (95% CI, 0.111-0.454; P = .001), with the largest effect observed in J-MINT, followed by FINGER and MAPT.
Multiple Mechanisms at Play
Healthy eating and exercise likely affect brain health through multiple mechanisms — possibly those related to cholesterol metabolism and vascular mechanisms, study investigator Jenni Lehtisalo, PhD, researcher at the Finnish Institute for Health and Welfare, Helsinki, Finland, told Medscape Medical News.
Lehtisalo noted that cognitive benefits among APOE ε4 carriers appeared consistent across diverse populations — Asian and European — and cognitive groups, including at-risk individuals and those with MCI. The research team plans to examine additional studies to see if these findings hold in more geographically and ethnically diverse populations.
These findings offer hope for patients with a family history of AD who may feel powerless to reduce their risk. Individuals can still act and benefit from lifestyle changes, Lehtisalo said. While carriers may derive greater benefit from lifestyle interventions, she emphasized that everyone gains from healthy habits.
The analysis could not determine which specific components of the intervention — physical activity, healthy diet, cognitive training, or risk factor monitoring — most benefited APOE ε4 carriers. Lehtisalo noted that healthy habits often cluster; for example, physically active individuals tend to eat healthier diets. The study also did not assess sex differences.
Commenting on the two studies for Medscape Medical News , Rebecca M. Edelmayer, PhD, vice president of Scientific Engagement at the Alzheimer's Association, noted the importance of understanding what puts people at risk for AD, including genetics.
'That's why looking at these associations between genetic risk and some type of lifestyle intervention is critical,' she said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

'It's a mess': Calgary pharmacists scrambling to help patients amid nationwide painkiller shortage
'It's a mess': Calgary pharmacists scrambling to help patients amid nationwide painkiller shortage

Yahoo

time3 hours ago

  • Yahoo

'It's a mess': Calgary pharmacists scrambling to help patients amid nationwide painkiller shortage

Canada is experiencing a nationwide shortage of some of the most widely prescribed painkillers, leaving Calgary pharmacists working to find creative solutions so patients aren't left in pain. Health Canada issued a notice this week warning that medications combining acetaminophen with codeine or oxycodone are in short supply. The shortage affects several widely used painkillers, including multiple strengths of Lenoltec (Tylenol 1, 2, 3 and 4). Acetaminophen with oxycodone is marketed in Canada by Teva Canada Limited, Apotex Inc. and Laboratoire Riva Inc. According to Health Canada, Teva is reporting a shortage due to manufacturing disruptions, while Apotex and Riva are facing shortages driven by increased demand. Acetaminophen with codeine is sold in different formats by Teva, Riva and Pharmascience Inc. Teva has reported shortages of Lenoltec, while Riva and Pharmascience are not officially short but cannot meet the surge in demand caused by Teva's supply issues, the notice states. 'As a result, acetaminophen with codeine or oxycodone may not always be available,' Health Canada said. At Luke's Drug Mart in Bridgeland, pharmacist David Brewerton said patients are 'frantic' as pharmacists work to mitigate the fallout of what he called a 'serious' shortage. 'We can't fill what we would like to be able to fill,' he said, noting the pharmacy only has 'tiny amounts' of Lenoltec in all strengths. 'We're looking anywhere from late August into October to get stock back in. 'We won't take a (prescription) transfer because we don't even have enough to supply the people that we're already supplying,' he said. 'It's a mess.' Brewerton noted the shortage is not new and has been going on for several months, forcing pharmacists to find solutions to mitigate the fallout. 'We've been finding workarounds in the majority of cases,' he said. 'Sometimes there are alternatives that we can put together that will match it. 'In other cases… there might be a different painkiller that they could use that would treat the same pain.' Pharmacists making adjustments, government looking for supply He notes drug shortages are not new, but said this one underscores the risks of relying heavily on a single manufacturer. 'The vast majority of the products we're talking about being short … is coming out of one company,' he said. 'If they're having a problem with what appears to be one particular ingredient that goes into making all those different types of tablets.. (and) suddenly they all go short, it's a domino effect.' He said the causes of drug shortages are 'incredibly varied' – from manufacturing disruptions to ingredient issues to worker strikes – and are difficult to predict. Diversifying supply, he said, is the best long-term safeguard. 'You want to diversify, so if there's a problem you're making up for it elsewhere,' he said. Health Canada said addressing the shortage is 'a top priority.' 'We recognize the importance of having acetaminophen with codeine or oxycodone products available for patients,' the notice states. 'We're communicating with health care providers, provincial and territorial governments, and distributors to coordinate the sharing of information about this shortage. 'We're also working with manufacturers and stakeholders to monitor the supply of acetaminophen with codeine or oxycodone and looking at options for increasing access to these products.' The Canadian Pharmacists Association has released a clinical guide to help pharmacies manage the shortage. In the meantime, local pharmacists like Brewerton are doing what they can to keep patients comfortable. 'Every pharmacist is having to deal with that right now. And we're all working on what we can do to make up whatever we need to do for patients,' he said. 'We'll do our best.'

Weekly spin class ‘better than physio' for people with common hip issue
Weekly spin class ‘better than physio' for people with common hip issue

Yahoo

time6 hours ago

  • Yahoo

Weekly spin class ‘better than physio' for people with common hip issue

Weekly group spin classes could be more beneficial than physiotherapy for people with a common hip problem, a study suggests. The approach could also be more cost-effective for the NHS and could help tackle waiting times for physiotherapy, according to researchers. Hip osteoarthritis happens when the cartilage in the hip breaks down, causing pain and stiffness. It it estimated that the condition affects about 3.2 million people in the UK. For the trial, experts from Bournemouth University and University Hospitals Dorset (UHD) compared usual physiotherapy care with an eight-week exercise and education programme known as Chain (cycling against hip pain). The study, published in The Lancet Rheumatology, included 211 people, with roughly half assigned to each group. The Chain group attended weekly education sessions from a physiotherapist, lasting around 30 minutes, followed by a 30-minute session of static cycling led by a gym instructor. The effects of treatment on patients were measured by the Hip Disability and Osteoarthritis Outcome Score (HOOS) activities of daily living (ADL) subscale, which assesses how hip problems affect various daily activities. The study found those who completed the cycling classes had a 'statistically significant improvement in patient-reported function after treatment'. Researchers said the method 'showed superior outcomes compared with usual physiotherapy care, and the feasibility of delivering a low-cost, community-based intervention within the NHS was shown'. However, they stress the 'longer-term benefits and broader generalisability warrant further investigation'. Tom Wainwright, a professor of orthopaedics at Bournemouth University and a physiotherapist at UHD, said: 'For the time it takes to treat one patient using standard physiotherapy, we can treat multiple patients in a group session and provide them with better outcomes. 'This has proved to be more cost-effective than standard treatment and so we hope this will contribute to reducing NHS waiting times for physiotherapy treatment in the future.' Professor Rob Middleton, of Bournemouth University and an orthopaedic surgeon at UHD, said: 'Hip replacements cost the NHS over £6,000 per patient, so avoiding surgery for hip problems reduces the burden on the NHS, saves money, and provides better outcomes for patients. 'Now with this new study we can also see the potential for static cycling to save further money for the NHS by bringing down waiting lists for physiotherapy.' Dr Peter Wilson, chief medical officer at UHD, said: 'We are an ageing population and increasingly we are seeing more patients with osteoarthritis that need either surgery or physiotherapy. 'Finding alternative ways to treat these patients could help reduce waiting times and the financial demand on NHS services.' The Chain intervention was first launched in 2013 and patients who wish to take part are referred to UHD from their GP. To bolster access on a national level, experts from Bournemouth University had developed a virtual course on their education app, allowing people to follow the programme from their home or local gym.

Medscape Readers Offer Their Opinion on UTI Management
Medscape Readers Offer Their Opinion on UTI Management

Medscape

time9 hours ago

  • Medscape

Medscape Readers Offer Their Opinion on UTI Management

I recently presented a clinical scenario of a 34-year-old woman who called the clinic after hours, reporting symptoms consistent with a urinary tract infection (UTI). The only in-person clinical care available at the time was the emergency department, and urgent care wouldn't open until the following morning. Given this history, I asked Medscape readers what they would do next. Thank you for the excellent participation and comments that you provided. It was wonderful to hear different perspectives. According to our reader poll, the most popular management option for this patient was a recommendation to visit the urgent care center on Saturday morning. This would be the most reasonable approach if there was some doubt as to the diagnosis of UTI. As I described in the previous article (and as one reader commented), there is a possibility that this patient might have a sexually transmitted infection, not a UTI. However, a brief screen for symptoms and sexual history could be performed over the phone and, if negative, would make the diagnosis of UTI much more likely. If clinical questioning indicates that the patient might be experiencing menopause, genitourinary syndrome of menopause (GSM) becomes a consideration. Among women, postmenopausal dysuria can have multiple etiologies, but clinicians should strongly consider GSM as a potential diagnosis. GSM is a term that describes the genital, sexual, and urinary symptoms that affect over 80% of postmenopausal women. These symptoms can include vaginal dryness and burning, dyspareunia, and dysuria. So, how can physicians differentiate GSM from UTI? I focus on the anatomical location of discomfort. Is it around the urethra and vagina or deeper in the suprapubic area? UTI is more likely to be associated with urinary urgency and frequency, but if GSM is accompanied by detrusor instability — another very common condition — the lines between diagnoses can continue to blur. Finally, a pelvic examination with evidence of vaginal atrophy would suggest GSM. In my professional opinion, GSM is not a consideration in our 34-year-old patient. Instead, I agree with the 27% of respondents who wanted to treat her empirically with nitrofurantoin. Nitrofurantoin is well-tolerated and one of the three preferred antibiotics for uncomplicated UTIs among women, according to the 2010 guidelines from the Infectious Diseases Society of America. The other first-line antibiotics for uncomplicated UTI were trimethoprim-sulfamethoxazole and fosfomycin. Of these three recommended antibiotics, nitrofurantoin and fosfomycin are associated with the lowest rates of antimicrobial resistance, and nitrofurantoin is generally more readily available in pharmacies than is fosfomycin. Fluoroquinolones are less preferred for the treatment of UTI because of higher rates of antimicrobial resistance. In a study of 3779 adults with UTI presenting to US emergency departments between 2018 and 2020, 22.1% of Escherichia coli isolates were resistant to fluoroquinolones. As one reader astutely noted, fluoroquinolones can also promote myalgia, tendonitis, and tendon rupture. As for beta-lactams, inferiority to fluoroquinolones for clinical cure rates of UTI and concerns regarding the promotion of extended-spectrum beta-lactamase resistance of gram-negative bacteria limit their use in the treatment of UTI. A new antibiotic, gepotidacin, was approved in March 2025 for the management of uncomplicated UTI among female patients aged 12 years or older. Investigators compared gepotidacin vs nitrofurantoin among 3136 women with UTI in two randomized controlled trials. The treatment course of both gepotidacin and nitrofurantoin was 5 days. The investigators found that gepotidacin was noninferior to nitrofurantoin in the outcome of treatment success (defined by symptomatic plus microbiologic success) in one of the trials, and superior to nitrofurantoin in the other trial. Of note, treatment success for resistant phenotypes of E coli generally favored gepotidacin. Diarrhea occurred in 14% and 18% of women treated with gepotidacin in the two studies, respectively, whereas 4% of women treated with nitrofurantoin developed nausea. Although UTI is one of the most common bacterial infections worldwide, it does not receive the attention from researchers and clinicians that it should. So, it is exciting to have a new class of antibiotic to offer women with UTI, and treatment guidelines are currently being updated to incorporate data regarding emerging treatments for UTI. The future is bright! As always, thank you for your contributions to this series.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store